Description

Farletuzumab is a humanized monoclonal antibody designed to target the folate receptor alpha (FRα). This compound is of significant interest in the development of targeted cancer therapeutics, particularly for ovarian and lung cancers where FRα is overexpressed. It is primarily utilized by pharmaceutical R&D teams, biotechnology companies, and clinical research organizations engaged in oncology drug development and precision medicine. The product is supplied under stringent quality controls to ensure consistency for research and development applications.

Application

• Oncology Research & Drug Development: Primary application in preclinical and clinical research for cancers overexpressing folate receptor alpha (FRα).
• Biopharmaceutical Manufacturing: Serves as a critical reference standard or active pharmaceutical ingredient (API) in the production of therapeutic antibody candidates.
• Diagnostic Assay Development: Used in the development of companion diagnostics and immunohistochemistry (IHC) assays to identify FRα-positive tumors.
• Mechanistic Studies: Employed in academic and industrial laboratories to study antibody-drug conjugate (ADC) mechanisms and FRα biology.
• Clinical Trial Materials: Supplied as a GMP-grade material for use in Phase I-III clinical trials investigating targeted cancer therapies.

Basic Information

Product Name	Farletuzumab
CAS No.	896723-44-7
Molecular Formula	C6440H9916N1704O2016S46
Molecular Weight	Approx. 145 kDa
Synonyms	MORAb-003; Anti-Folate Receptor Alpha Monoclonal Antibody; Farletuzumab (USAN); hFR1; Humanized Monoclonal Antibody MORAb-003; Immunoglobulin G1, anti-(human folate receptor 1) (human-mouse monoclonal MORAb-003 γ1-chain), disulfide with human-mouse monoclonal MORAb-003 κ-chain, dimer
EINECS	Contact for details

Quality Control

Our Farletuzumab is manufactured and tested under a quality management system. Each batch is characterized to ensure identity, purity, potency, and stability, meeting specifications suitable for research and development use. Certificates of Analysis (COA) detailing results for purity (by SEC-HPLC and CE-SDS), endotoxin levels, sterility, binding affinity (SPR or ELISA), and protein concentration are provided. We support development activities with data packages aligned with regulatory expectations for investigational products.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized material at -20°C or below. Reconstituted solutions should be aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles. The product is hygroscopic (moisture-sensitive) and should be handled in a controlled, dry environment. Always refer to the specific batch Certificate of Analysis for detailed storage and handling instructions.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (Mass Spec)	Conforms
Purity (SEC-HPLC)	≥ 95.0% (Monomer)
Purity (CE-SDS, Reduced)	Heavy Chain & Light Chain bands present
Protein Content (A280)	90% - 110% of label claim
Endotoxin	< 1.0 EU/mg
Sterility (USP)	Sterile
Binding Activity (ELISA/SPR)	Conforms to reference standard

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.